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Circulating glycosyltransferases including xylosyltrans-
ferases I (XylT1) and II (XylT2) are potential serum
biomarkers for various diseases. Understanding what in-
fluences the serum activity of these enzymes as well as
the sources of these enzymes is important to interpreting
the significance of alterations in enzyme activity during
disease. This article demonstrates that in the mouse and
human the predominant XylT in serum is XylT2. Further-
more, that total XylT levels in human serum are approx-
imately 200% higher than those in plasma due in part to
XylT released by platelets during blood clotting in vitro.
In addition, the data from Xylt2 knock-out mice and mice
with liver neoplasia show that liver is a significant source
of serum XylT2 activity. The data presented suggest that
serum XylT levels may be an informative biomarker in pa-





Xylosyltransferases (EC 2.4.2.26), one of the earliest glycosyl-
transferases described, initiate the assembly of glycosaminogly-
can chains to the core proteins of proteoglycans by catalyzing
the transfer of xylose from the nucleoside diphosphate donor
(UDP-xylose) to designated serine residues in the protein ac-
ceptor substrate (reviewed in Wilson (2004)). In mammals, two
active isoenzymes exist (Götting et al. 2000; Cuellar et al. 2007;
Pönighaus et al. 2007; Voglmeir et al. 2007) each consisting of
a type II transmembrane protein thought to reside in the endo-
plasmic reticulum and/or cis-Golgi (reviewed in Wilson (2004)).
Subsequent to xylosylation, a tetrasaccharide linker is made on
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which the assembly of chondroitin sulfate, heparan sulfate, der-
matan sulfate, and heparin occurs. Both xylosyltransferases I
and II (XylT1 and XylT2, respectively) have stem regions like
other glycosyltransferases (Paulson and Colley 1989; Kleene
and Berger 1993) that are susceptible to proteolytic cleavage
allowing the enzymes to exit the cell’s Golgi apparatus and
ultimately to enter the circulation (Götting et al. 1999).
Altered serum XylT activity has been proposed as a biomarker
of altered proteoglycan metabolism in various diseases rang-
ing from diabetes to systemic sclerosis (Götting et al. 2007).
Increased fibrosis or/and accumulation of extracellular matrix
components including proteoglycans in affected tissues occurs
in these conditions leading to the speculation that increased
serum XylT activity represents increased proteoglycan biosyn-
thesis (Götting et al. 1999; 2007). Similarly, decreased serum
XylT activity has also been found in diabetic patients suggesting
that decreased XylT activity (Götting et al. 2008) may contribute
to the decrease in proteoglycans in diabetic nephropathy (Raats
et al. 2000). It is uncertain which isoenzyme(s) are responsi-
ble for the steady-state level of XylT activity in normal serum
and which are responsible for the increased serum activities in
various disease states. Higher serum XylT activity is reported
in pseudoxanthoma elasticum (PXE) patients and attributed to
XylT1. However, no proof that this isoenzyme is responsible
for the increased XylT activity is given (Götting et al. 2005).
Polymorphisms in XYLT1 are associated with PXE and dia-
betic nephropathy (Schön, Prante, et al. 2006; Schön, Schulz,
et al. 2006). An XYLT1 coding region G > T polymorphism
is associated with increased serum XylT levels in PXE patients
(Schön, Schulz, et al. 2006). In contrast, it is also associated with
decreased serum glycosaminoglycans and normal serum XylT
levels in normal subjects (Ambrosius et al. 2008). Confusingly,
polymorphisms in XYLT2 have also been reported to occur in a
subset of PXE patients with greater organ involvement (Schön,
Schulz, et al. 2006). Therefore, which isoenzyme predominates
in the serum of healthy individuals and patients and from which
tissue it arises is unclear. To better understand the potential
utility of serum XylT activity as a biomarker, we investigated
which isoenzymes were present in normal serum and what may
be source(s) of alteration of XylT activity during disease. Us-
ing the recently published Xylt2 knock-out mouse (Xylt2−/−)
(Condac et al. 2007) and known differences in nucleotide ac-
ceptor affinities (Götting et al. 1998; Casanova et al. 2008), we
show for the first time that the predominant circulating isoen-
zyme in mice and humans is XylT2 and that human platelets
during clot formation in vitro significantly contribute to total
serum XylT activity levels. Our previous studies have shown
that the liver is primarily dependent on XylT2 for proteogly-
can biosynthesis (Condac et al. 2007). This report demonstrates
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Table I. Serum XylT activity
Xylt2+/+ Xylt2−/− Human
BIKp 227.71 ± 37.48 1.10 ± 0.30a,c 75.14 ± 4.74
L-APPp 9.13 ± 1.59 0.29 ± 0.14b,c 4.32 ± 0.38
mU/L ± standard deviation; Xylt2+/+mice, n = 5; Xylt2−/− mice, n = 5;
Human, n = 4.
aP < 0.0001 as compared to Xylt2+/+ using BIKp as a substrate.
bP < 0.0001 as compared to Xylt2+/+ using L-APPp as a substrate.
cAverage dpm readings were greater than 2-fold above background.
that in a mouse model of liver neoplasia serum XylT activity
decreases implicating the liver as a significant contributor to to-
tal serum XylT activity. This report is the first identification of
in vivo sources of serum XylT activity and the first experimental
demonstration of a disease impacting a specific organ leading
to changes in serum XylT activity levels.
Results and discussion
XylT2 is the predominant isoenzyme in serum
To investigate the relative contribution of XylT2 and XylT1
to serum XylT activity levels, serum total XylT activ-
ity was determined in Xylt2−/− mice (Table I). XylT as-
says using the well-known bikunin nuclear acceptor peptide
(BIKp)(QEEEGSGGGQKK) (Weilke et al. 1997) showed in
Xylt2−/− mice that the total XylT activity is decreased ≈99% as
compared to Xylt2+/+ mice. This strongly suggests that XylT2
is the predominant isoenzyme in mouse serum and that XylT2
may also be the predominant XylT isoenzyme in human serum.
The relative contribution of each human isoenzyme to serum
XylT activity was examined by exploiting known differences
in substrate affinities between human XylT1 and XylT2. As-
says using the BIKp or similar peptides show comparable KM
values for human XylT1 and XylT2. Human XylT1 from JAR
cells and Pichia pastoris conditioned media have KM values of
22 μM (Götting et al. 1998) and 2.5 μM (Casanova
et al. 2009), respectively. Human XylT2 from P. pastoris con-
ditioned media has KM values of 1.9 μM (Casanova et al. 2008)
and 6.1 μM (Casanova et al. 2009). Therefore, the BIKp is not a
differential acceptor substrate for the human XylT isoenzymes
but is a good acceptor substrate for total XylT activity mea-
surements. However, 3-A4-amyloid protein precursor protein
peptide (L-APPp) (TENEGSGLTNIK) is reported to be a much
better acceptor substrate for human XylT1 (KM of 20.1 μM)
than for human XylT2 (KM > 10,000 μM) (Götting et al. 1998;
Casanova et al. 2008). Thus, measurements using the BIKp ac-
ceptor would detect total activity due to both human isoenzymes
and those with L-APPp would detect only XylT1. Interestingly,
the results showed that XylT1 activity in human serum using
L-APPp is 6% of serum total XylT activity as assayed with BIKp
(Table I). Similarly in Xylt2+/+ mice sera, assays with L-APPp
suggest that XylT1 constitutes approximately 4% of the serum
total XylT activity (Table I). Taken together, these data indicate
that XylT activity in normal human and mouse serum is due
primarily to the XylT2.
Mouse XylT1 and XylT2 kinetics
Mouse XylT assays using the BIKp and L-APPp assume con-
served kinetics between the mouse and human isoenzymes for
Fig. 1. Mouse XylT1 and XylT2 have similar KM for BIKp and L-APP. Left
panels show plots for XylT1 and right panels for XylT2. The reaction velocity
was measured using increasing concentrations of acceptor substrate and
saturating levels of UDP-xylose (see Materials and Methods).
these substrates. Intriguingly, using L-APPp on Xylt2+/+ and
Xylt2−/− sera showed higher XylT1 values in Xylt2+/+ mice
than in Xylt2−/− mice (Table I). This suggests that indeed XylT1
activity levels differ between wild-type and mutant mice or that
our assumptions regarding similar affinities between the mouse
and human isoenzymes for BIKp and L-APPp are incorrect.
Therefore, we determined the kinetics of the mouse isoenzymes
for the BIKp and L-APPp (Figure 1). Kinetics of recombinant
forms of mouse XylT1 and XylT2 (rmXylT1 and rmXylT2)
showed these isoenzymes had KM values of 20.48 μM and
11.72 μM, respectively, for the BIKp. These values are compa-
rable to those reported for human XylT1 and XylT2 as described
above using BIKp and similar bikunin peptides. However, the
KM values for rmXylT1 and rmXylT2 using L-APPp as the ac-
ceptor substrate showed that rmXylT1 and rmXylT2 had similar
KM values of 213.2 μM and 390.5 μM, respectively, in contrast
to previous studies of the human isoenzymes showing that hu-
man XylT1 has a much greater affinity for L-APPp than human
XylT2. For both mouse isoenzymes, these results indicate that
the BIKp is a better acceptor substrate than L-APPp, and that de-
spite 93.4% homology in amino acid sequences between mouse
and human XylT2 (Pönighaus et al. 2007) some species differ-
ences in substrate specificities may exist.
Total XylT activity is higher in serum than plasma
Given the potential utility of serum XylT activity as a biomarker
in several diseases, understanding the influences on and the
source(s) of serum XylT activity is important in clarifying the
significance of serum XylT levels in predicting disease severity
and in determining the etiologic role of XylT1 and XylT2 in
these diseases. Because serum and plasma differ considerably
biochemically, there is likelihood that these differences could
augment XylT activity, and depending on how blood samples
are collected and processed, these differences may affect XylT
measurements. As shown in Figure 2, serum and plasma total
XylT activities do differ. In Xylt2+/+ mice, total serum XylT
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Fig. 2. XylT activity is greater in serum than plasma. Using the BIKp, serum
(black bars) and plasma (white bars) XylT activity measured in males of
multiple species including amphibians consistently shows higher levels in
serum. In all cases the difference was statistically significant as indicated by
the asterisk. (M) Mouse P = 0.015, n = 5; (H) Human P = 0.0000007, n = 4;
(B) Baboon P = 0.0025, n = 4; (P) Porcine P = 0.002, n = 4; (C) Canine P =
0.02, n = 4; (E) Equine P = 0.015, n = 3; (X) Xenopus P = 0.00008, n = 5.
Table II. Human platelet XylT activity
Treatment Supernatant Pellet
No thrombin None detected 42.9 ± 9.21
Thrombin 33.73a ± 5.96 5.51 ± 0.99
mU/1012 platelets ± standard deviation, n = 4.
aP < 0.0001 as compared to thrombin activated pellet.
BIKp is the acceptor substrate.
activity was found to be 42% higher than plasma. Moreover,
Figure 2 shows increased serum total XylT activity as compared
to plasma levels in multiple species including humans where
values are 200% higher in serum. Interestingly, in the Xylt2−/−
mice, no significant difference between serum and plasma total
XylT activity was found (1.10 mU/L, n = 5, versus 0.84 mU/L,
n = 5, P = 0.23). Although these values are at the lower limits of
detection possibly leading to undistinguishable differences, the
loss of XylT2 in the Xylt2−/− mice results in the loss of most if
not all of the detectable differences between serum and plasma.
These results show that in all species checked total XylT levels
are higher in serum than plasma and that in mice this difference
is most likely due to XylT2.
Platelets are a significant contributor to serum total XylT
activity
During in vitro clot formation, activated platelets release fac-
tors from their α-granules leading to the formation of serum
(Harrison and Cramer 1993). Higher total XylT activity in serum
as compared to plasma suggests that platelets may be an impor-
tant source of XylT activity. To examine this, gel-filtered human
platelets were collected from normal volunteers and the XylT
activity released from these cells upon activation was measured
and compared to XylT activity present in unactivated platelets
(Table II). These experiments found that unactivated platelets
harbor significant XylT activity that is released upon activation
with thrombin. Therefore, XylT released from platelets is one
reason why serum total XylT activity is higher than plasma total
XylT levels. This also suggests that diseases affecting platelet
activation may alter serum total XylT activity.
Liver is one contributor to serum total XylT activity
Human HepG2 liver cells secrete XylT activity (Götting et al.
1998) and these cells predominately express XYLT2 (Cuellar
et al. 2007) suggesting that XylT activity in these cells arises
from XylT2. Using the BIKp, total XylT activity of 23.71 ±
8.89 μU/mg protein in HepG2-conditioned media was found to
exceed that present in the cells at 1.45 ± 0.30 μU/mg protein.
Therefore, HepG2 cells are very efficient at releasing XylT sug-
gesting that in vivo liver cells may contribute significant XylT
activity to circulating levels. Notably, previous observations in
the Xylt2−/− mice demonstrate that XylT2 is the predominate
liver isoenzyme for hepatocellular proteoglycan biosynthesis
(Condac et al. 2007) and as shown above, these mice have es-
sentially no serum total XylT activity. These findings further
suggest that the liver is a major source of serum XylT2 ac-
tivity. However, since the Xylt2−/− mice lack XylT2 activity
in all tissues, these studies do not address the contribution of
nonhepatic tissues to serum XylT2 activity. If the liver is an
important source of circulating XylT2 activity, alterations in
liver homeostasis may significantly impact serum total XylT
measurements. To examine this question, we measured serum
total XylT activity in mice with liver neoplasia. In the mouse
model used, the mice have transgenes for liver-directed expres-
sion of c-Myc and metallothionein promoter-driven expression
of TGFα leading to the development of hepatocellular carcino-
mas (Murakami et al. 1993). Interestingly, we found reduced
total XylT activity in sera from mice possessing visible tumors
(77.68 ± 30.89 mU/L, n = 3) as compared to controls (159.95 ±
15.24 mU/L, n = 3) (average ± SD, P = 0.01). These exper-
iments further suggest that the liver is a significant source of
circulating XylT2 activity and that under conditions of liver
disease, serum XylT2 activity can be reduced likely due to de-
creased secretion by the dysfunctional liver.
Conclusions and perspectives
There is a growing literature describing alterations in serum
XylT levels associated with diseases that have significant fibro-
sis and/or turnover of the extracellular matrix. Secreted XylT
has no currently known function and likely does not include pro-
teoglycan biosynthesis since donor UDP-monosaccharides are
known not to be present in significant amounts outside the Golgi
apparatus (Varki et al. 2009). Although highly speculative, re-
leased XylT may represent a byproduct of increased secretory
activity by certain cells types. Although a byproduct, it may still
be clinically important. Determining the clinical utility of serum
XylT levels with respect to disease will come from knowing its
source(s) and what may affect its activity. This report shows
first that the predominant human and mouse circulating XylT
isoenzyme is XylT2. Second we show that serum total XylT
activity levels are higher than plasma levels in part due to the
XylT released during platelet activation which in the mouse is
XylT2, and third we show that the liver is a significant source
for circulating XylT2 levels. These results indicate that factors
and disease conditions that affect platelet activation and/or liver
function could affect total serum XylT activity. Notably, given
the tissue distribution of XylT2 gene expression (Condac et al.
2007; Pönighaus et al. 2007), additional sources other than the
liver may contribute to circulating XylT2 activity. Furthermore,
XylT1 activity may contribute to total XylT serum activity in
those diseases that affect specific tissues known to express Xylt1
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(e.g., kidney and spleen) (Condac et al. 2007; Pönighaus et al.
2007). Therefore, serum XylT activity in patients with specific
diseases needs to be examined using isoenzyme-specific tools,
e.g., XylT isoenzyme-specific antibodies and/or differential ac-
ceptor substrates. Correlation of XylT isoenzyme changes with
tissue-specific changes for each disease would give insight into
the cell type and biochemical mechanism(s) responsible for al-
terations in total serum XylT activity in disease.
Material and methods
Materials
The Xylt2−/− mice were generated as previously described
(Condac et al. 2007) and the c-Myc/TGFα doubly transgenic
mice were generated as previously described (Murakami et al.
1993). All mice were housed in facilities accredited by the As-
sociation for Assessment and Accreditation of Laboratory Ani-
mal Care International. The Institutional Animal Care and Use
Committee approved all animal procedures and experiments.
All reagents were obtained from Sigma-Aldrich (St Louis, MO)
unless otherwise specified.
Serum and plasma collection
Using isoflurane, mouse blood was collected by heart puncture.
For plasma, blood was collected into sodium citrate or K3 EDTA
and centrifuged at 8000 × g. For serum, blood was incubated
for 30 min at room temperature then centrifuged at 8000 × g
for 15 min. Frogs (Xenopus laevis) were anesthetized by 0.05%
benzocaine followed by blood collection from the heart. Plasma
and serum samples were prepared similar to those for the mouse.
Human blood from normal male volunteers 25–55 years of age
was collected in BD Vacutainer SST for serum and BD Vacu-
tainer K3 EDTA for plasma. Blood samples from baboons, dogs,
pigs, and horses were collected into sodium citrate or K3 EDTA
for plasma and no anticoagulant for serum. All animal samples
were obtained from nongonadectomized males except for the
horses which were geldings. Plasma and serum samples were
stored at −80◦C until assayed. Multiple freezing and thawing
were avoided by thawing the samples and immediately perform-
ing assays. The University of Oklahoma Health Sciences Center
Institutional Review Board approved all procedures for human
experiments.
XylT assays
To measure XylT activity, cell lysates (50 μL), conditioned me-
dia (50 μL), serum (10–25 μL), or plasma (10–25 μL), platelet
supernatant (10–30 μL), and platelet pellet (10–30 μL) were in-
cubated with 1.13 μM UDP-[14C]-D-xylose 150–250 mCi/mol
(Perkin Elmer, Waltham, WA), 7.46 μM UDP-D-xylose (Car-
boSource, University of Georgia, Atlanta, GA) and 160 μM
acceptor peptide (BIKp or L-APPp) (Bio-Synthesis, Lewisville,
TX) in a total reaction volume of 100 μL containing 25 mM
2-(4-morpholino)-ethane sulfonic acid, pH 6.5, 25 mM KCl,
5 mM KF, 5 mM MgCl2, 5 mM MnCl2 for 1 h at 37◦C. The
reaction was stopped by placing reactions on ice. BSA, 1.5 mg,
was added as a carrier and the reaction product was precipi-
tated with 10% trichloroacetic acid/4% phosphotungstic acid
(Pfeil and Wenzel 2000). After 30 min incubation on ice, tubes
were centrifuged and the precipitates were washed twice with
750 μL trichloroacetic acid 5%, incubated 15 min at 4◦C, and
centrifuged 15 min at 12,000 × g. Radioactivity was measured
in the final precipitates after resuspension in 400 μL of 1N
NaOH. One unit of enzymatic activity represents the incor-
poration of 1 μmol xylose/min into the acceptor peptide. For
each sample, the reactions were done in duplicate or triplicate.
Michaelis–Menten constants were determined with the purified
rmXylT protein from Chinese hamster ovary cells and saturating
levels of UDP-xylose. Recombinant mouse XylT was incubated
with various concentrations of acceptor peptides indicated,
1.13 μM UDP-[14C]-D-xylose, and 7.46 μM cold UDP-D-
xylose. All values were determined in duplicate. A nonlinear
regression fit of the Michaelis–Menten plot was used to cal-
culate the KM using GraphPad Prism version 5.01, GraphPad
Software, San Diego, CA.
Human platelet XylT activity
Blood was drawn immediately into citrate dextrose (38.1 mM
citric acid, 74.8 mM Na3 citrate, 136 mM glucose), and gel-
filtered platelets were prepared as described (Alberio et al.
2000). Platelets were counted and equal numbers for each donor
were activated with thrombin 0.5 U/mL for 15 min at 37◦C
followed by centrifugation at 9000 × g for 10 min. Super-
natants were transferred to new tubes and the cellular pellets
were washed with 500 μL Tris-HCl 20 mM, pH 7.5, and cen-
trifuged again. Final pellets were homogenized in 50 μL of
2-(4-morpholino)-ethane sulfonic acid 25 mM, pH 6.5, 25 mM
KCl, 5 mM KF, 5 mM MgCl2, 5 mM MnCl2, 0.1% Triton-X
100. Samples of 10–30 μL of supernatants and homogenized
pellets were used for enzyme assays.
Recombinant mouse XylT
The Xylt2 expression construct was a modification of the mini-
gene construct previously described (Cuellar et al. 2007). The
modified minigene used produced a protein lacking the 45 N-
terminal amino acids including the transmembrane domain as
predicted by comparison with the human XylT2-predicted trans-
membrane domain (Wilson 2004) and from Kyte–Doolittle hy-
drophobicity predictions. The Xylt1 expression cassette pro-
duced a protein that was lacking 94 N-terminal amino acids in-
cluding the transmembrane domain which was predicted as for
XylT2. Both Xylt1 and Xylt2 expression cassettes were cloned
into a modified pcDNA3.1 vector (Invitrogen, Carlsbad, CA)
containing a transferrin signal peptide and an HPC4 epitope
tag in frame on the N-terminus that was used for immunopu-
rification. Reading frames of both constructs were verified by
sequencing (see supplementary data for more detail).
Supplementary Data
Supplementary data for this article is available online at
http://glycob.oxfordjournals.org/.
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